Table 1 Efficacy of immune checkpoint inhibitors in melanoma brain metastases
Author | Phase | Agent | No. Patients | Intracranial ORR (%) |
|---|---|---|---|---|
Margolin (2012) | II | Ipi | ||
Cohort A | 51 | 16 | ||
Cohort B | 21 | 5 | ||
Di Giacomo (2012) | II | Ipi + Fotemustine | 20 | 50 |
Parakh (2017) | Real-world (retrospective) | Nivo or Pembro | 66 | 21 |
Kluger (2019) | II | Pembro | 23 | 26 |
Long (2017) | II | |||
Cohort A | Ipi + Nivo | 26 | 46 | |
Cohort B | Nivo | 25 | 20 | |
Cohort C | Nivo | 16 | 6 | |
Tawbi (2018) | II | Ipi + Nivo | 94 | 55 |